We’re not there yet, but the downtrend seems to be exhausted. Now a break of the downtrend (black arrow) AND the resistance area of NOK 20,50/21,- needs to happen and a potential W-formation is formed (see orange scenario).
Look for weekly close above 37
We just broke significant resistance trend line (orange). Met first resistance at emission price at 37,50,- The breakout has moved us closer to DNBs target at 68,-
Price currently in a symmetrical triangle, making lower highs and higher lows. Expecting a breakout to the upside, if the price breaks out of the triangle. Take profit 1: 45.90 Take profit 2: 51.85 Careful! if price breaks below the triangle, do not enter a trade. This stock is in an uptrend, and that's why we are only looking to buy.
"Covid-19 potential road to market"
This is a trading plan based on price action. Keep in mind that BerGenBio will present updates on their current cancer treatment 25th june. This could boost the price extremely, because of the high volatility. 37.15 will be the safest price to enter a possible trade. That's why I am waiting for a pullback before entering.
BGBIO is a biotech company with focus on cancer treatment. Like most biotech it is extremely volatile for news, but often fluctuate between key buy and sell zones when no news are evident. BGBIO is presenting news on their cancer treatment 25th of june. They are currently first in line to do a free test in ACCORD - the British rushed testing setup for...
Biotech company based i Norway/UK Listed on OSE BergenBio`s Bemcentinib now in UK financed Covid-19 studym, Fast track ACCORD. Number og study ongoing: 15 3 big: * ACCORD Covid-19 * Bemcentinib/Keytruda combo whit Merck i NSCLC. * AML 9 of 15 sponsored studies. Tecnicaly potent, whit big upside potential. Fair value at the moment 86nok. Archtic Securities.
Quote: "Bemcentinib has shown effect against SARS-CoV-2 (coronavirus) in animal models and has been selected as the first of six drugs to be fast-tracked in the new UK initiative (ACCORD) to enter a phase 2 study directly. Although there are many uncertainties around valuing this opportunity, we estimate the new indication adds NOK 21/share, with a new TP of NOK...
ABOUT BERGENBIO OSL:BGBIO BerGenBio is a clinical-stage oncology company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. www.bergenbio.com www.nordnet.no Trinity Delta Analysis: www.trinitydelta.org
BerGenBio OSL:BGBIO is a norwegian clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. The stock is currently in a short term uptrend that could provide a new test of important resistance, where a...
Overordnet jobber kursen i en negativ trend, med konsolideringer som er fine å trade. Pt ligger det et fint RSI brudd i chartet som indikerer videre oppgang, først til den røde trendlinjen dernest toppen av konsoliderings rangen. Det som taler litt i mot videre oppgang kommende uke, er volumutvikling og en bearish candlestick fra siste børsdag før påske.